These are top 10 stocks traded on the Robinhood UK platform in July
SAN DIEGO - Neurocrine Biosciences, Inc. (NASDAQ:NBIX), a biopharmaceutical company with a market capitalization of $11 billion and impressive revenue growth of nearly 25% over the last twelve months, revealed new study results at the 2025 Psychiatry Update Conference in Chicago, indicating that INGREZZA (valbenazine) capsules may lead to remission of tardive dyskinesia (TD) symptoms in a significant number of patients. According to InvestingPro analysis, the company maintains a strong financial health score of "GREAT," positioning it well in the competitive pharmaceutical market. The research, derived from the KINECT 4 clinical trial, showed that after 48 weeks of treatment, 59.2% of participants achieved remission as defined by a proposed threshold using the Abnormal Involuntary Movement Scale (AIMS).
The post-hoc analysis included data from 103 participants who completed the trial, assessing remission of TD symptoms across different doses and psychiatric diagnoses. Both 40 mg and 80 mg doses of INGREZZA showed substantial improvements in AIMS total scores, with mean baseline scores declining markedly by Week 48. The remission rates were consistent irrespective of the underlying psychiatric condition, with 57.7% of participants with schizophrenia or schizoaffective disorder and 62.5% with mood disorders reaching remission.
KINECT 4 is a Phase 3, open-label study involving 163 participants with moderate to severe TD who received open-label treatment with INGREZZA for 48 weeks, followed by a four-week washout period. The medication was generally well-tolerated, and the most common treatment emergent adverse events (TEAEs) were urinary tract infection and headache.
TD is a movement disorder characterized by uncontrollable, abnormal, and repetitive movements, often caused by long-term use of antipsychotics. INGREZZA, a selective vesicular monoamine transporter 2 (VMAT2) inhibitor, is approved by the U.S. Food and Drug Administration for treating adults with TD and chorea associated with Huntington’s disease. The company’s strong market position is reflected in its robust financial metrics, with a current ratio of 3.4 indicating excellent liquidity to fund ongoing research and development. For deeper insights into Neurocrine’s financial health and growth potential, investors can access comprehensive analysis through InvestingPro’s detailed research reports.
This study’s findings, based on a press release statement, suggest that INGREZZA could be an effective long-term treatment for TD, offering hope for patients affected by this disorder. However, it is important to note that the long-term safety and efficacy of INGREZZA require further evaluation in larger, controlled studies. With the stock currently trading near its 52-week low and showing potential upside according to analyst targets, InvestingPro data suggests the stock may be undervalued relative to its growth prospects. Discover more exclusive insights and 10+ additional ProTips by accessing the full Pro Research Report.
In other recent news, Neurocrine Biosciences has announced the initiation of a Phase 1 clinical trial for NBI-1140675, a new VMAT2 inhibitor aimed at treating neurological and neuropsychiatric conditions. This trial will evaluate the safety and efficacy of the compound, adding to the company’s portfolio of neurological treatments. Additionally, Neurocrine Biosciences has approved a $500 million share repurchase program, following the completion of a previous $300 million buyback. This move aligns with their strategy to balance investment in product development and shareholder returns.
In analyst updates, RBC Capital Markets revised its price target for Neurocrine Biosciences to $139, down from $148, due to increased restrictions on Ingrezza, a key product. Deutsche Bank has initiated coverage with a Hold rating and a $138 price target, citing the fair valuation of the company’s stock. Meanwhile, UBS adjusted its price target to $154 from $176, maintaining a Buy rating, suggesting that the recent sell-off may have been excessive. The UBS analyst remains optimistic about the stock’s potential, despite conservative growth projections for Ingrezza.
These developments come as Neurocrine Biosciences continues to focus on expanding its pipeline and managing its capital allocation strategy.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.